Syed Saad Mahmood, MD🫀 (@saadmahmoodmd) 's Twitter Profile
Syed Saad Mahmood, MD🫀

@saadmahmoodmd

Cardiologist / CadioOncologist. System-Director #CardioOnc at @StFrancis_LI @CHS_LI

ID: 3239097700

linkhttps://www.linkedin.com/in/ssmahmood calendar_today06-05-2015 16:01:13

1,1K Tweet

1,1K Followers

396 Following

Ahmad Masri (@masriahmadmd) 's Twitter Profile Photo

Unfortunate to see the ODYSSEY HCM trial not meeting its primary endpoints (KCCQ/pVO2). We will need to understand what drove the outcome here. news.bms.com/news/details/2… #cardiotwitter

Unfortunate to see the ODYSSEY HCM trial not meeting its primary endpoints (KCCQ/pVO2). We will need to understand what drove the outcome here. 

news.bms.com/news/details/2…

#cardiotwitter
Abdelrahman Ali (@abdelcards) 's Twitter Profile Photo

Excited for the 2nd Middle East #CardioOncology Congress in 🌟Dubai🌟! Honored to serve on the Scientific Committee and collaborate with the esteemed Dr. Hadi Skouri 💼🫀 Grateful to be part of this growing community! ✨ #CardioTwitter 🌍🎗️ Hani Jneid MD Anita Deswal Cezar Iliescu

Excited for the 2nd Middle East #CardioOncology Congress in 🌟Dubai🌟! Honored to serve on the Scientific Committee and collaborate with the esteemed <a href="/HSkouri/">Dr. Hadi Skouri</a> 💼🫀 Grateful to be part of this growing community! ✨ #CardioTwitter 🌍🎗️ <a href="/docHJ/">Hani Jneid MD</a> <a href="/anita_deswal/">Anita Deswal</a> <a href="/cezar_ciliescu/">Cezar Iliescu</a>
JACC Journals (@jaccjournals) 's Twitter Profile Photo

Quality of care metrics for #CardioOnc practice: The need for standardization and improvement in the management of patients with cancer. Methodology proposed by the ACC/AHA: jacc.org/doi/10.1016/j.… #JACCCardioOnc #cvEcho

Quality of care metrics for #CardioOnc practice: The need for standardization and improvement in the management of patients with cancer. Methodology proposed by the ACC/AHA: jacc.org/doi/10.1016/j.…

#JACCCardioOnc #cvEcho
Syed Saad Mahmood, MD🫀 (@saadmahmoodmd) 's Twitter Profile Photo

🚨 *St Francis Heart Center, NY CardioOncology Journal Club* Tomas G. Neilan, MD, MPH (Mass General Heart) joined us to discuss mechanistic insight from STOP-CA trial on statin’s cardioprotection from anthracyclines: Watch episode: opci.live/cardio-oncolog… #CardioOnc St. Francis Hospital & Heart Center Catholic Health

🚨 *St Francis Heart Center, NY CardioOncology Journal Club*

<a href="/TomasNeilan/">Tomas G. Neilan, MD, MPH</a> (<a href="/MGHHeartHealth/">Mass General Heart</a>) joined us to discuss mechanistic insight from STOP-CA trial on statin’s cardioprotection from anthracyclines:

Watch episode: opci.live/cardio-oncolog…

#CardioOnc <a href="/StFrancis_LI/">St. Francis Hospital & Heart Center</a> <a href="/CHS_LI/">Catholic Health</a>
Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review Early diagnosis and correct treatment selection are critical in AL management sciencedirect.com/science/articl…

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review

Early diagnosis and correct treatment selection are critical in AL management

sciencedirect.com/science/articl…
Ahmed Bennis (@drbennisahmed) 's Twitter Profile Photo

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum jacc.org/doi/10.1016/j.…

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome: The FINE-HEART Pooled Analysis

The nonsteroidal MRA finerenone reduced the risk of new-onset AF/AFL across the CKM spectrum

jacc.org/doi/10.1016/j.…
Radcliffe Cardiology (@radcliffecardio) 's Twitter Profile Photo

Don’t miss the #CardioOnc IC-OS Journal Club live TODAY at 14:00 BST | 09:00 EDT! 🔗 ow.ly/Hvrh50VIV8O Experts will discuss the latest findings on discontinuing cardioprotective therapy in patients with improved CTRCD. 💬 Join Dr Hyukjin Park, Dr Jose Alvarez-Cardona, Dr

Don’t miss the #CardioOnc IC-OS Journal Club live TODAY at 14:00 BST | 09:00 EDT! 🔗 ow.ly/Hvrh50VIV8O

Experts will discuss the latest findings on discontinuing cardioprotective therapy in patients with improved CTRCD.

💬 Join Dr Hyukjin Park, Dr Jose Alvarez-Cardona, Dr
Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo

#HeartFailure2025 #LBCT by Marianna Fontana #HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM #MedIQHF2025

#HeartFailure2025 #LBCT by <a href="/MariannaFonta11/">Marianna Fontana</a> 

#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM
 
#MedIQHF2025